Role of Interleukin-6 in the Antigen-Specific Mucosal Immunoglobulin A Responses Induced by CpG Oligodeoxynucleotide-Loaded Cationic Liposomes

Overview

Journal Membranes (Basel)

Date 2022 Jun 23

PMID 35736342

Authors

Rui Tada

Emi Honjo

Shoko Muto

Noriko Takayama

Hiroshi Kiyono

Jun Kunisawa

Yoichi Negishi

Affiliations

Soon will be listed here.

Abstract

An advantage of mucosal vaccines over conventional parenteral vaccines is that they can induce protective immune responses not only at mucosal surfaces but also in systemic compartments. Despite this advantage, few live attenuated or inactivated mucosal vaccines have been developed and applied clinically. We recently showed that the intranasal immunization of ovalbumin (OVA) with class B synthetic oligodeoxynucleotides (ODNs) containing immunostimulatory CpG motif (CpG ODN)-loaded cationic liposomes synergistically exerted both antigen-specific mucosal immunoglobulin A (IgA) and systemic immunoglobulin G (IgG) responses in mice. However, the mechanism underlying the mucosal adjuvant activity of CpG ODN-loaded liposomes remains unknown. In the present study, we showed that the intranasal administration of CpG ODN-loaded cationic liposomes elicited interleukin (IL)-6 release in nasal tissues. Additionally, pre-treatment with an anti-IL-6 receptor (IL-6R) antibody attenuated antigen-specific nasal IgA production but not serum IgG responses. Furthermore, the intranasal administration of OVA and CpG ODN-loaded cationic liposomes increased the number of IgA/CD138 plasma cells and IgA/B220 B cells in the nasal passages. This increase was markedly suppressed by pre-treatment with anti-IL-6R blocking antibody. In conclusion, IL-6 released by CpG ODN-loaded cationic liposomes at the site of administration may play a role in the induction of antigen-specific IgA responses by promoting differentiation into IgA plasma cells for IgA secretion from B cells.

References

Aoshi T . Modes of Action for Mucosal Vaccine Adjuvants. Viral Immunol. 2017; 30(6):463-470. PMC: 5512297. DOI: 10.1089/vim.2017.0026. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

Suzuki H, Kondoh M, Yagi K, Kiyono H, Kunisawa J . [The development of mucosal vaccine using bacterial function for targeting mucosal tissues]. Yakugaku Zasshi. 2014; 134(5):629-34. DOI: 10.1248/yakushi.14-00006-3. View

Kunisawa J, Gohda M, Kiyono H . [Uniqueness of the mucosal immune system for the development of prospective mucosal vaccine]. Yakugaku Zasshi. 2007; 127(2):319-26. DOI: 10.1248/yakushi.127.319. View

Greene C, Hu J, Vance D, Rong Y, Mandell L, King-Lyons N . Enhancement of humoral immunity by the type II heat-labile enterotoxin LT-IIb is dependent upon IL-6 and neutrophils. J Leukoc Biol. 2016; 100(2):361-9. PMC: 4945353. DOI: 10.1189/jlb.3A0415-153RR. View

Fauci A . Infectious diseases: considerations for the 21st century. Clin Infect Dis. 2001; 32(5):675-85. DOI: 10.1086/319235. View

Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J . Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice. BMC Res Notes. 2017; 10(1):68. PMC: 5270218. DOI: 10.1186/s13104-017-2380-8. View

Boyaka P, McGhee J . Cytokines as adjuvants for the induction of mucosal immunity. Adv Drug Deliv Rev. 2001; 51(1-3):71-9. DOI: 10.1016/s0169-409x(01)00170-3. View

Cerutti A . The regulation of IgA class switching. Nat Rev Immunol. 2008; 8(6):421-34. PMC: 3062538. DOI: 10.1038/nri2322. View

10.

Bromander A, Ekman L, Kopf M, Nedrud J, Lycke N . IL-6-deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection. J Immunol. 1996; 156(11):4290-7. View

11.

Boyaka P, Marinaro M, Jackson R, Menon S, Kiyono H, Jirillo E . IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol. 1999; 162(1):122-8. View

12.

Fauci A, Touchette N, Folkers G . Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases. Emerg Infect Dis. 2005; 11(4):519-25. PMC: 3320336. DOI: 10.3201/eid1104.041167. View

13.

Tada R, Hidaka A, Tanazawa Y, Ohmi A, Muto S, Ogasawara M . Role of interleukin-6 in antigen-specific mucosal immunoglobulin A induction by cationic liposomes. Int Immunopharmacol. 2021; 101(Pt A):108280. PMC: 8553392. DOI: 10.1016/j.intimp.2021.108280. View

14.

Tada R, Ogasawara M, Yamanaka D, Sakurai Y, Negishi Y, Kiyono H . Enzymatically polymerised polyphenols prepared from various precursors potentiate antigen-specific immune responses in both mucosal and systemic compartments in mice. PLoS One. 2021; 16(2):e0246422. PMC: 7870002. DOI: 10.1371/journal.pone.0246422. View

15.

Mihara M, Takagi N, Takeda Y, Ohsugi Y . IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol. 1998; 112(3):397-402. PMC: 1904997. DOI: 10.1046/j.1365-2249.1998.00612.x. View

16.

Borges O, Lebre F, Bento D, Borchard G, Junginger H . Mucosal vaccines: recent progress in understanding the natural barriers. Pharm Res. 2009; 27(2):211-23. DOI: 10.1007/s11095-009-0011-3. View

17.

Rhee J, Lee S, Kim S . Mucosal vaccine adjuvants update. Clin Exp Vaccine Res. 2013; 1(1):50-63. PMC: 3623511. DOI: 10.7774/cevr.2012.1.1.50. View

18.

Mora J, von Andrian U . Differentiation and homing of IgA-secreting cells. Mucosal Immunol. 2008; 1(2):96-109. DOI: 10.1038/mi.2007.14. View

19.

Tada R, Ohshima A, Tanazawa Y, Ohmi A, Takahashi S, Kiyono H . Essential Role of Host Double-Stranded DNA Released from Dying Cells by Cationic Liposomes for Mucosal Adjuvanticity. Vaccines (Basel). 2020; 8(1). PMC: 7157664. DOI: 10.3390/vaccines8010008. View

20.

Cazac B, Roes J . TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity. 2000; 13(4):443-51. DOI: 10.1016/s1074-7613(00)00044-3. View